Regulatory effect of traditional Chinese medicine on gut microbiota in patients with atherosclerosis
A protocol for systematic review and meta-analysis

Langlang Huang, PhD\textsuperscript{a}, Jianan Wang, MM\textsuperscript{b}, Ri Xu, MM\textsuperscript{b}, Yanwei Liu, PhD\textsuperscript{b}, Zhongyang Liu, MM\textsuperscript{b},∗

Abstract
Background: Atherosclerosis is the pathological basis of many cardiovascular and cerebrovascular diseases, and its pathogenesis is complex. Recent studies revealed a significant role of gut microbiota in the onset and development of atherosclerosis. Traditional Chinese medicine has rich clinical experience and unique advantages in the treatment of atherosclerosis. A large number of studies have proved that traditional Chinese medicine has the functions of reducing blood lipid, regulating gut microbiota, and resisting inflammation. The aim of this systematic review is to observe the randomized controlled trial of traditional Chinese medicine in treating gut microbiota, so as to evaluate the effectiveness and safety of traditional Chinese medicine in treating atherosclerosis patients.

Methods: The English database (PubMed, Web of Science, Embase, the Cochrane Library) and Chinese database (China National Knowledge Infrastructure, the Chongqing VIP Chinese Science, and Technology Periodic Database, Wanfang Database, and China Biomedical Literature Database) will be searched up to October 2020. We will also manually search the Chinese clinical trial register, conference papers, and unpublished studies or references. Randomized control trials of traditional Chinese medicine treatment of atherosclerosis were collected comprehensively, and 2 researchers will independently screen literature, data extraction, and evaluation the quality of literature methodology. The primary outcomes are lipid metabolism and gut microbiota and their metabolites. The secondary outcomes are the change of inflammatory markers. Meta-analysis was performed by RevMan 5.3.5 software. The Grades of Recommendation, Assessment, Development, and Evaluation will be used to evaluate the outcome quality of evidence.

Results: This study will comprehensively review the existing evidence of traditional Chinese medicine in treating atherosclerosis from the perspective of gut microbiota.

Conclusion: This study will provide information on the effectiveness and safety of traditional Chinese medicine in treating atherosclerosis from the perspective of gut microbiota.

Unique INPLASY number: INPLASY2020110056.

Abbreviations: AS = atherosclerosis, BAs = bile acids, GM = gut microbiota, RCT = randomized controlled trial, SCFAs = short-chain fatty acids, TCM = traditional Chinese medicine, TMAO = trimethylamine N-oxide.

Keywords: atherosclerosis, gut microbiota, protocol, systematic review, traditional Chinese medicine

1. Introduction
Atherosclerosis (AS) is a chronic inflammatory disease related to lipid accumulation and changes in a blood vessel wall components, which occurs in large and medium arteries. It is the pathological basis of many cardiovascular and cerebrovascular diseases such as ischemic heart disease, cerebral infarction, and cerebral hemorrhage. With the development of the social economy and the aggravation of population aging, its incidence rate increases, which causes higher mortality and social pressure in the world.\textsuperscript{(1)} According to statistics, about 17 to 18 million
people die of atherosclerotic cardiovascular disease every year in the world, accounting for 31% of all deaths; In China, the number of cardiovascular disease patients reached 300 million.\cite{1,2} The pathogenesis of AS is unclear, and the risk factors include smoking, drinking, hypertension, hyperlipidemia, and obesity, among which abnormal lipid metabolism is the most critical risk factor.\cite{3,4} This disease’s pathogenesis is complex, involving lipid infiltration, endothelial injury, platelet hyperfunction, inflammatory reaction, oxidative stress, and so on.\cite{5} However, neither theory can fully explain the formation mechanism of AS alone.

There are more than 3,500 kinds of gut microbiota (GM) in normal human intestines, with a total of about 100 trillion. GM’s stable composition and function play an essential role in maintaining the intestinal tract’s normal physiological part and immune defense.\cite{6} With the deepening of related research, more and more evidence shows that GM imbalance can lead to the formation of AS by participating in the regulation of cholesterol metabolism, oxidative stress, and inflammation\cite{7-10,11}; Moreover, GM can also participate in the metabolism of nutrients such as protein, dietary fiber, and choline in vivo, and produces metabolites such as trimethylamine N-oxide (TMAO), short-chain fatty acids, and bile acids (BAs) to regulate the immunity and metabolism of host, thus affecting the occurrence and development of AS.\cite{12,13}

Traditional Chinese medicine (TCM), as the crystallization of Chinese conventional wisdom, has multi-component, multi-target, and multi-channel characteristics and plays a unique role in clinical prevention and treatment of diseases. Many modern pharmacological studies have proved that TCM has the functions of protecting vascular endothelial cells, resisting platelet aggregation, reducing blood lipid, resisting inflammation, resisting oxidative stress, and regulating GM.\cite{14-16} After oral administration of TCM, its practical components are mainly absorbed in the intestinal tract, and stay in the intestinal tract for a long time, which is beneficial to regulating GM diversity and metabolism. Moreover, TCM can also play an anti-AS role by regulating the metabolites of GM, such as reducing the production of TMAO and increasing the ratio of lactic acid bacteria bifidobacteria to promote BA metabolism and slow down the AS process.\cite{17}

In recent years, although many reviews have summarized the effects of TCM on GM and AS and related clinical trials and basic research have been carried out,\cite{18,19} there is no systematic review of the effects of TCM on AS from the perspective of GM regulation. The purpose of this study is to systematically review randomized controlled trials (RCTs) on TCM intervention in treating AS patients to evaluate the effectiveness and safety index, and incidence of adverse events.

2. Methods

2.1. Protocol and registration

The protocol has been registered on the INPLASY website, and the registration number is INPLASY202011056 (URL https://inplasy.com/inplasy-2020-11-056/). This report will be performed by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols.\cite{20,21}

2.2. Literature search

We will search the following databases from their inception onwards to the October 2020: PubMed, Web of Science, Embase, the Cochrane Library, China National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, Wanfang Database, and China Biomedical Literature Database. We will also manually search the Chinese Clinical Trial Register, conference papers, and unpublished studies or references. The search strategy for PubMed is listed in Table 1, a similar method will be applied to the Chinese database.

2.3. Inclusion criteria

According to the Participants’ principle, Intervention, Comparison, and Outcome, the following standards are formulated.

2.3.1. Type of studies. RCTs on TCM intervention in treating AS patients will be included in this review.

2.3.2. Type of participants. Patients who meet the diagnostic criteria for AS will be included.

2.3.3. Types of interventions. The treatment group was treated with TCM or TCM combined with western medicine.

2.3.4. Type of comparators. The control group will receive western medicine treatment or without intervention and was not treated with TCM.

2.3.5. Types of outcome measures. The lipid metabolism outcome indicators (TG, TC, HDL-C, LDL-C, HDL, LDL, ApoA1, ApoB) and GM and its metabolites (GM structure and diversity, TMAO, short-chain fatty acids, BA) are the primary outcome indicators of this study. This study’s secondary outcome include carotid intima-media thickness, atherosclerotic plaque area, inflammatory factor level (such as TNF-α, CRP, IL-6), safety index, and incidence of adverse events.

2.4. Exclusion criteria

(1) TCM combined with other non-drug adjuvant therapies (such as tai chi, acupuncture, and moxibustion);

(2) Documents with similar original data and repeated publication;

(3) Documents for which accurate data cannot be obtained;

(4) Case report, conference papers, and summaries;

(5) No RCT

2.5. Studies selection

Two researchers in the research group independently searched out the literature. First, identical pieces of literature were screened and excluded by Endnote X9 document management software. The summary of the title exclusion system was read, and finally, the full text was read, which met the inclusion criteria. In case of disagreement, the third author discussed and decided together. The selection process will be shown according to the Preferred Reporting Items for Systematic Review and Meta-Analysis flow chart in Figure 1.

2.6. Data extraction and management

After the literature was included, 2 other researchers independently completed the data extraction, including the author’s name, year of publication, title, country, average age, gender, study design, the total number of cases, participants, intervention

Table 1
PubMed search strategy.

| Number | Search terms |
|--------|--------------|
| #1     | Atherosclerosis[MeSH] |
| #2     | Atherosclerosis[title/abstract] |
| #3     | Atherosclerosis[MeSH] |
| #4     | #1 OR #2 OR #3 |
| #5     | Gastrointestinal Microbiome[MeSH] |
| #6     | Gut Microbiome[title/abstract] |
| #7     | Microbiome, Gastrointestinal[title/abstract] |
| #8     | #5 OR #6 OR #7 |
| #9     | Gut Microbiome[title/abstract] |
| #10    | Microbiome, Gut[title/abstract] |
| #11    | Gut Microflora[title/abstract] |
| #12    | Microflora, Gut[title/abstract] |
| #13    | Gut Microbiota[title/abstract] |
| #14    | Microbiota, Gut[title/abstract] |
| #15    | Gastrointestinal Flora[title/abstract] |
| #16    | Flora, Gastrointestinal[title/abstract] |
| #17    | Flora, Gut[title/abstract] |
| #18    | Flora, Gut[title/abstract] |
| #19    | Gastrointestinal Microbiota[title/abstract] |
| #20    | Gastrointestinal Microbiome[title/abstract] |
| #21    | Microbiota, Gastrointestinal[title/abstract] |
| #22    | Gastrointestinal Microbial Community[title/abstract] |
| #23    | Gastrointestinal Microbial Communities[title/abstract] |
| #24    | Microbial Community, Gastrointestinal[title/abstract] |
| #25    | Gastrointestinal Microflora[title/abstract] |
| #26    | Microflora, Gastrointestinal[title/abstract] |
| #27    | Gastric Microbiome[title/abstract] |
| #28    | Gastric Microbiota[title/abstract] |
| #29    | Microbiome, Gastric[title/abstract] |
| #30    | Intestinal Microbiome[title/abstract] |
| #31    | Intestinal Microbiota[title/abstract] |
| #32    | Microbiome, Intestinal[title/abstract] |
| #33    | Intestinal Microbiota[title/abstract] |
| #34    | Intestinal Microbiota[title/abstract] |
| #35    | Microbiota, Intestinal[title/abstract] |
| #36    | Intestinal Microbiota[title/abstract] |
| #37    | Microflora, Intestinal[title/abstract] |
| #38    | Intestinal Flora[title/abstract] |
| #39    | Flora, Intestinal[title/abstract] |
| #40    | Enteric Bacteria[title/abstract] |
| #41    | Bacteria, Enteric[title/abstract] |
| #42    | #4 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 |
| #43    | Traditional Chinese Medicine[title/abstract] |
| #44    | Chung I Hsing[title/abstract] |
| #45    | Hsueh, Chung[title/abstract] |
| #46    | Traditional Chinese Medicine, Chinese[title/abstract] |
| #47    | Traditional Chinese Medicine, Chinese[title/abstract] |
| #48    | Ming Yi Xue[title/abstract] |
| #49    | Chinese Traditional Medicine[title/abstract] |
| #50    | Chinese Traditional Medicine[title/abstract] |
| #51    | Traditional Tongue Diagnosis[title/abstract] |
| #52    | Tongue Diagnoses, Traditional[title/abstract] |
| #53    | Tongue Diagnosis, Traditional[title/abstract] |
| #54    | Traditional Tongue Diagnoses[title/abstract] |
| #55    | Traditional Tongue Assessment[title/abstract] |
| #56    | Tongue Assessment, Traditional[title/abstract] |
| #57    | Traditional Tongue Assessments[title/abstract] |
| #58    | Traditional Chinese Medicine[title/abstract] |
| #59    | randomized controlled trial[Publication Type] |
| #60    | randomized[Title/Abstract] |
| #61    | placebo[Title/Abstract] |
| #62    | #59 OR #60 OR #61 |
| #63    | #4 AND #42 AND #58 AND #62 |

2.7. Quality assessment of the studies
According to the bias risk evaluation standard of randomized controlled trials provided by Cochrane Handbook,23 the literature quality evaluation is carried out, which includes the following 6 aspects: random sequence generation, allocation concealment, blinding of participants, care-givers, outcome assessors, incomplete outcome data, selective outcome reporting, and other bias. According to the specific scoring rules, the 2 researchers evaluated 3 types: “low risk,” “high risk,” and “uncertain risk.” If there is any difference in quality evaluation, discuss it with the third author.

2.8. Measures of treatment effect
According to the different variables, the dichotomous variables are expressed as risk ratio and 95% confidence intervals. Continuous variables are defined as weighted mean difference or standardized mean difference and 95% confidence intervals.

2.9. Management with missing data
If there are insufficient or lost data, we will first contact the original author by email or telephone. If the lost data cannot be obtained, we will discard the unusable data and only analyze the available data.

2.10. Assessment of heterogeneity
The heterogeneity test adopts $P \leq .10$ and $I^2 \geq 50\%$ as the significance judgment criteria, and when $P > .10$ and $I^2 < 50\%$, the fixed effects models will be used for data analysis. If $P \leq .10$ and $I^2 \geq 50\%$, the random effects model will be chosen.

2.11. Data synthesis
RevMan5.3.5 software will be used for this meta-analysis. According to the heterogeneity level included in the study, the fixed-effect model or the random effect model was selected. We will conduct a meta-analysis of at least 3 qualified standards. Otherwise, if only 1 or 2 studies met the inclusion criteria, meta-analysis will not be undertaken, but the descriptive analysis will be adopted. If more than 10 articles are included, the inverted funnel diagram is used to analyze publication bias.

2.12. Sensitivity analysis
We consider sensitivity analysis for methodological quality and test the results’ robustness by excluding the risk of low quality and high bias.
2.13. **Subgroup analysis**

If heterogeneity is observed in the study, we will use subgroup analysis for research.

2.14. **Summary of evidence**

The evidence quality of each result is evaluated by the method of Recommendation, Assessment, Development, and Evaluation.[24] The evaluation will be divided into 4 qualities: “very low,” “low,” “medium,” or “high.”

2.15. **Ethical approval and dissemination**

Ethical approval is not necessary for this study because there is no individual data will be used. The research results will be published in a peer-reviewed journal and conference presentations.

3. **Discussion**

AS belongs to the category of “Mai Bi” in TCM. The theory of TCM holds that the interior and exterior of the heart and intestine, so it is possible to treat heart diseases by regulating GM. TCM has less toxic and side effects in the prevention and treatment of AS. With the development of sequencing technology and metagenome research, many studies have confirmed that TCM can regulate GM and its metabolites and resist AS. However, there is no systematic evaluation of RCTs on the role of TCM in AS treatment from the perspective of GM. Therefore, we hope that this study can provide the latest evidence for the effectiveness and safety of TCM in treating AS and regulating of GM and its metabolites and being used to guide clinical practice.

**Author contributions**

Conceptualization: Langlang Huang, Zhongyong Liu.
Data curation: Langlang Huang, Jianan Wang, Ri Xu.
Formal analysis: Jianan Wang, Ri Xu, Yanwei Liu.
Investigation: Langlang Huang, Zhongyong Liu.
Methodology: Langlang Huang, Jianan Wang, Ri Xu, Yanwei Liu.
Software: Jianan Wang, Yanwei Liu.
Supervision: Langlang Huang, Zhongyong Liu.
Writing – original draft: Langlang Huang, Jianan Wang, Yanwei Liu, Zhongyong Liu.
Writing – review & editing: Langlang Huang, Jianan Wang, Ri Xu.

References

[1] Stavnsbo M, Resaland GK, Andersen SA, et al. Reference values for cardiometabolic risk scores in children and adolescents: suggesting a common standard. Atherosclerosis 2018;278:299–306.

[2] Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers 2019;5:56–74.

[3] The Writing Committee of the Report on Cardiovascular Health Diseases in China. Report on Cardiovascular Health and Diseases in China 2019: an Updated Summary. Chin Circ J 2020;35:833–54.

[4] Rahman F, Al RFM, Blaha MJ, et al. Relation of diastolic blood pressure and coronary artery calcium to coronary events and outcomes (from the multi-ethnic study of atherosclerosis). Am J Cardiol 2017;120:1797–803.

[5] Schoemaker MH, Kleemann R, Morrison MC, et al. Casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-. Leiden mice. PLoS One 2017;12:e0180648.

[6] de Ronde MWJ, Kok MGM, Moerland PD, et al. High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis. Atherosclerosis 2017;263:377–84.

[7] Holdt LM, Teupser D. Long noncoding RNA ANRIL: Lnc-ing genetic variation at the chromosome 9p21 locus to molecular mechanisms of atherosclerosis. Front Cardiovasc Med 2018;5:145.

[8] Lassinger-Herfurth A, Pontarollo G, Grill A, et al. The gut microbiota in cardiovascular disease and arterial thrombosis. Microorganisms 2019;7:691.

[9] Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014;509:183–8.

[10] Elce A, Amato F, Zarrilli F, et al. Butyrate modulating effects on proinflammatory pathways in human intestinal epithelial cells. Benef Microbes 2017;8:841–7.

[11] Chistakov DA, Bobryshev YV, Kozarov E, et al. Role of gut microbiota in the modulation of atherosclerosis-associated immune response. Front Microbiol 2015;6:671.